Richard Freed III, MBA Co-Founder & CEO Prior to founding RheumaGen in 2019, Richard spent a decade with DuPont where he led biotech venture launches, consulted for healthcare management, and oversaw M&A transactions. As Venture Manager for the largest joint venture in DuPont’s Industrial Biotech portfolio, Richard helped guide a $200M+ JV with BP that was developing gene-edited yeast cells to produce isobutanol, a much higher value product than ethanol.